LeanBio Therapeutics, Inc. — SEC Form D Filing

LeanBio Therapeutics, Inc. filed an SEC Form D on October 22, 2026 in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 22, 2026
Round stage
Seed, as the company is leveraging SEC Rule 506(b) equity financing to establish early operational capacity and expand service offerings.
Industry
Biotechnology
Website
https://leanbio.net

What the company does

Securities: Equity. Revenue: No Revenues. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Biotechnology and pharmaceutical companies struggle with the complex, capital-intensive process design and scalable manufacturing required to bring novel biologic drugs to market.

Solution

LeanBio Therapeutics provides specialized contract development and manufacturing services to design, optimize, and produce biopharmaceutical products for drug developers.

Why now

The explosion of novel biologics pipeline candidates requires flexible, specialized biomanufacturing capacity that emerging biotech firms cannot efficiently build in-house.

Source: SEC EDGAR Form D filing